← Leaderboards
Zhiyong Yang
Fzata, Inc.
$10,414,299
Attributed
$18,343,715
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2017–24$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$18,343,715 · 8
By mechanism
R01$8,100,504 · 1
R44$7,532,664 · 3
UG3$2,091,549 · 1
R43$618,998 · 3
Top collaborators
- Hanping Feng7 shared
- Kevin W Garey3 shared
- Hua Yu3 shared
- Feng Wei1 shared
Others in their field
Other Emerging Leaders on “Future”
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- John E West · University Of Texas At Austin$128,483,161
- Beth Baseler · Leidos Biomedical Research, Inc.$117,364,154
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
Research focus
FutureResponseAntibioticsTreatment EfficacyInfectionClostridium DifficileDrug KineticsRecurrenceCessation Of LifeSeverity Of IllnessToxinStandard CareLeadPharmaceutical PreparationsAntibiotic ResistanceToxicologyBasePublic HealthBusinessesAnimalsClinical DevelopmentGut MicrobiotaProduct DevelopmentRegulation
Grant awards (20)
A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome$2,091,549
UG3 · FY2024 · NS · contact PI
Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)$950,520
R44 · FY2023 · DK · contact PI
A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)$923,175
R44 · FY2023 · AI · contact PI
A Yeast-based Immunotherapy against Clostridioides difficile infection$906,503
R44 · FY2023 · AI · contact PI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$1,008,708
R01 · FY2022 · AI · contact PI
A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)$988,488
R44 · FY2022 · AI · contact PI
A Yeast-based Immunotherapy against Clostridioides difficile infection$932,749
R44 · FY2022 · AI · contact PI
Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)$855,001
R44 · FY2022 · DK · contact PI
A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II)$999,996
R44 · FY2021 · AI · contact PI
A Yeast-based Immunotherapy against Clostridioides difficile infection$554,355
R44 · FY2021 · AI · contact PI
Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)$252,416
R44 · FY2021 · DK · contact PI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$167,253
R01 · FY2021 · AI · contact PI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$2,154,339
R01 · FY2020 · AI · contact PI
A Yeast-based Immunotherapy against Clostridioides difficile infection$169,461
R44 · FY2020 · AI · contact PI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$2,138,618
R01 · FY2019 · AI · contact PI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$1,170,960
R01 · FY2018 · AI · contact PI
Novel Immunotherapies for Comorbidity of Clostridium difficile and Inflammatory Bowel Disease$224,999
R43 · FY2018 · AI · contact PI
A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridium difficile Infection$168,931
R43 · FY2018 · AI · contact PI
A Novel Humanized Tetra-specific Antibody against Clostridium difficile Infection$1,460,626
R01 · FY2017 · AI · contact PI
A Yeast based Immunotherapy against Clostridium difficile Infection$225,068
R43 · FY2017 · AI · contact PI